1314241-10-5

1314241-10-5 structure

Name: Orticumab
Chemical Name: Orticumab
CAS Number: 1314241-10-5
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Inflammation/Immunology
Create Date: 2023-03-10 11:20:19
Modify Date: 2024-01-23 18:53:19
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].

Name	Orticumab

Description	Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology
In Vitro	Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体[1]。
In Vivo	Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色[1]。 Animal Model: B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] Dosage: 10 mg/mouse Administration: Intraperitoneal injection; once weekly for 3 weeks Result: Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.
References	[1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863. [2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.

No Any Chemical & Physical Properties